Currently the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system.

Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. TSI is developing a range of immune-modulatory agents to target certain cancers, and other diseases.

**StemVacs Immunotherapy Platform**

*An immuno-oncology cellular therapy that programs the immune system to selectively attack malignant cells.*

In February 2015 TSOI and Pan Am Cancer Treatment Centers developed manufacturing capabilities and a clinical protocol for a compassionate use utilization of StemVacs in 10 patients with advanced cancer completing the clinical in early 2016.

In collaboration with Pan Am, the Company is in the process of generating GCP documentation for modifying the previously treated 10 patients into a Phase I Trial, which is compliant with the FDA as part of an Ex-US trial compliant with 21 CFR 312.120 Foreign clinical studies not conducted under an IND.

**“Right To Try”**

*Legislation that gives terminally ill patients the right to use experimental medications*

Our Ex-US compliant clinical will allow us to immediately offer the StemVacs Platform to any patients that qualify under RTT.

**“Right To Try Cancer Clinic”**

*The Company Seeks Funding to Open Cancer Clinic in San Diego*

Although many licensing opportunities will exist, the Company desires to physically open a clinic to treat the first patients in the USA with StemVacs. There is currently no known insurance that will cover the costs of treatment, so this is fee-for-service based care, one of the many benefits of the new law. Including the removal of all liability for drug maker and physician alike.

**Future Licensing Opportunities**

*Right To Try is Law of the Land*

Effective immediately RTT is the law of the land and therefore our Platform can be made available in all 50 States. Licensing could involve the single oncologist to clinics and other alternative medicine facilities.

**What is the StemVacs Platform?**
StemVacs is a platform for antigen-nonspecific immune modulatory treatment that can be utilized as a monotherapy or as a combination with antigen-specific modalities such as peptide or protein-based vaccines. The PlatForm consists of 5 components that are phased as part of the overall protocol.

**NanoStilbene:** A patented product developed by the Company as an immunotherapy adjuvant.

**MemoryMune:** Reawakens dormant immune memory cells.

**LymphoBoost:** A proprietary formulation of Mifepristone, a drug approved for another indication, which we have shown to be capable of stimulating lymphocytes, particularly NK cells and T cells, both critical in maintaining anti-tumor immunity.

**StemVacs:** A subcutaneously administered vaccine comprised of immune stimulatory peptides resembling cancer stem cell-specific proteins.

**innaMune:** This is a biological product derived from tissue culture of blood cells derived from healthy donors. It is a combination of cytokines that maintain activity of the innate immune system cells, as well as having the ability to shift M2 macrophages to M1.

The overarching approach to cancer on the StemVacs Platform is as follows:

1) Treat innate immune suppression: Administration of oral NanoStilbene to decrease immune suppressive toxic molecules made by tumor and tumor microenvironment.

2) Treat adaptive immune suppression: Administration of MemoryMune to activate dormant memory cells recognizing the tumor. Administration of LymphoBoost to repair deficient IL-12 production.

3) Stimulation of immune response to cancer stem cells (StemVacs).

4) Consolidation and maintenance of immunity: Cycles of StemVacs, supported by innaMune and LymphoBoost.

---

**Management Team & Board of Directors**

- Timothy G. Dixon – President, CEO, & Chairman
- Gerry B. Berg – Vice President, CFO, Director
- Thomas E. Ichim, Ph.D. – Director
- James Veltmeyer, MD – Chief Medical Officer
- Hong Ma, MD, Ph.D., M.B.A. – Chief Scientific Officer

**Scientific Advisory Board**

- Santosh Kesari, MD, PhD – Neuro-oncologist
- Francesco Marincola, MD – Tumor Immunology
- Pablo Guzman, MD – Cardiologist
- Nassir Azimi, MD – Cardiologist
- Barry Glassman, DMD – Dentist
- Vijay Mahant, PhD – Biochemist
- David P. Hajjar, PhD – Biochemist

---

**Intellectual Property**

- 07-08-15 Augmentation of Oncology Immunotherapies by Pterostilbene Containing Compositions
- 09-02-15 Preventative Methods and Therapeutic or Pharmaceutical Compositions for the Treatment or Prevention of Pregnancy Complications
- 09-15-15 Diagnostic Methods For The Assessment Of Pregnancy Complications
- 09-25-15 A Medical Device For Reducing The Risk Of Preterm-Labor And Preterm-Birth
- 11-20-15 Exosome Mediated Innate and Adaptive Immune Stimulation for Treatment of Cancer
- 04-27-16 Augmentation Of Stem Cell Activity Using Pterostilbene And Compositions Containing Pterostilbene
- 03-29-17 Stimulation of Immunity to Tumor Stem Cell Specific Proteins by Peptide Immunization
- 03-29-17 Targeting the Tumor Microenvironment through Nutraceutical Based Immunoadjuvants
- 03-29-17 Activated Leukocyte Extract for Repair of Innate Immunity in Cancer Patients
- 03-29-17 Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof
- 03-29-17 Methods of Re-Activating Dormant Memory Cells with Anticancer Activity
- 10-08-17 Synergistic Inhibition of Glioma Using Pterostilbene and Analogues Thereof